Cantor Fitzgerald Brokers Lift Earnings Estimates for Elutia

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share (EPS) estimate for Elutia to ($0.52), improving from a prior estimate of ($0.65).
• Elutia recently reported ($0.26) EPS for the last quarter, which fell short of analyst expectations of ($0.17).
• Institutional investors hold 74.03% of Elutia's stock, reflecting significant institutional interest in the company.

Elutia Inc. (NASDAQ:ELUT - Free Report) - Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Elutia in a research note issued to investors on Tuesday, August 19th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($0.52) per share for the year, up from their prior estimate of ($0.65). The consensus estimate for Elutia's current full-year earnings is ($1.74) per share.

Elutia (NASDAQ:ELUT - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). The business had revenue of $6.26 million during the quarter, compared to the consensus estimate of $6.55 million.

Separately, Lake Street Capital reduced their price target on Elutia from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $8.00.

Elutia Trading Up 1.4%

ELUT stock traded up $0.03 during trading on Thursday, reaching $2.42. The stock had a trading volume of 26,418 shares, compared to its average volume of 35,629. Elutia has a 52 week low of $1.61 and a 52 week high of $5.12. The stock's 50 day moving average is $2.04 and its two-hundred day moving average is $2.28. The firm has a market cap of $102.78 million, a PE ratio of -2.29 and a beta of 0.88.

Institutional Trading of Elutia

Several institutional investors have recently made changes to their positions in ELUT. OMERS ADMINISTRATION Corp purchased a new stake in shares of Elutia during the first quarter worth about $28,000. XTX Topco Ltd bought a new position in Elutia during the second quarter valued at approximately $28,000. Jane Street Group LLC bought a new position in Elutia during the first quarter valued at approximately $48,000. Arcus Capital Partners LLC bought a new position in Elutia during the first quarter valued at approximately $51,000. Finally, Northern Trust Corp boosted its stake in Elutia by 30.0% during the fourth quarter. Northern Trust Corp now owns 17,957 shares of the company's stock valued at $67,000 after buying an additional 4,148 shares during the last quarter. Hedge funds and other institutional investors own 74.03% of the company's stock.

About Elutia

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.